ESR1 and neoplasm: ERβ (NR3A2) is a second estrogen receptor; however, conversely to ERα whose expression increases at the early stages of BCa and acts as a tumor promoter, ERβ is reduced during carcinogenesis and cancer progression and seems to act as a tumor suppressor [26].